Principal Scientist (Infectious Disease)
Immunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoimmune disease. We are developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs.
It is an exciting time to join Immunocore. Our most advanced oncology therapeutic candidate, tebentafusp, has demonstrated an overall survival benefit in a randomized Phase 3 clinical trial in metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies. The company also recently completed its Initial Public Offering and was listed on the NASDAQ.
- Contribute to the Infectious Diseases (ID) strategy and advancement of the ID portfolio, driving activities to leverage Immunocore’s technology for therapeutic and / or diagnostic applications.
- Devise and lead the generation of ID-relevant in vitro models, including co-culture systems and organoid cultures, together with appropriate pathogen-specific read-outs, to evaluate on-target activity of ImmTAX molecules.
- Recommend, provide rationale and drive studies to probe the biology of immune cell-pathogen interactions that are pertinent to project priorities and company goals.
- Lead high risk / high reward collaborations with experts in academia / industry to advance or complement in-house disease-relevant models and build proof of concept for ImmTAX in ID indications
- Contribute to preclinical cell biology package (pharmacology / toxicology) for ImmTAX candidates; deliver comprehensive data package and study interpretation sufficient to support regulatory filing.
- Proactively research scientific literature, databases and clinical data to enable evaluation of ImmTAX potential in new ID indications, build competitive intelligence and potentially implement novel technologies that could support ID research activities
- Drive cross-departmental initiatives to accelerate advancement of ImmTAX molecules, including exploring opportunities at the interface between ID and Oncology or Autoimmune Disease.
- Develop manuscripts for publication through to completion, lead external presentations.
- Depending on projects allocated, work at containment level 3 laboratory (CL3) may be required. Post-holder would be required to ensure compliance with relevant legislation and local policies relating to CL3 activities; guide the development of risk assessments, SOPs and policies for CL3 work
EXPERIENCE AND KNOWLEDGE
- In depth expertise and proven track record in ID disease biology (ideally virology)
- Expertise in cell and molecular biology (qPCR, cloning, T cell cloning, flow cytometry, functional experiments, primary cell cultures).
- Expertise and leadership in immune assay technologies.
- Evidence of scientific contribution to ID disease biology in the form of scientific publications and conference presentations
- Tissue disaggregation, explant or organoid cultures experience.
- Experience in next-gen sequencing
EDUCATION & QUALIFICATIONS
- Essential: PhD in cell biology, virology, immunology, or related discipline.
- Alternatively, a B.S. or M.S. with significant work experience in relevant scientific areas and a record of scientific accomplishment (e.g., project progression, published manuscripts and/or abstracts).
- Essential: Relevant industrial or post-doctoral academic experience